Saturable transport of H2-antagonists ranitidine and famotidine across Caco-2 cell monolayers.
The purpose of this study was to investigate the mechanism by which the H2-antagonists ranitidine and famotidine interacted with the paracellular space during their transport across Caco-2 cell monolayers. Transport experiments with ranitidine and famotidine across Caco-2 cell monolayers were performed to determine the apical-to-basolateral flux at various concentrations. Kinetic analysis of the transport data showed that ranitidine and famotidine were transported by both saturable and nonsaturable processes. Na+, K+-ATPase inhibitor ouabain and metabolic inhibitors sodium azide + 2-deoxy-D-glucose did not affect ranitidine transport, suggesting that the active transport was not involved. Famotidine and some other guanidine-containing compounds, e.g., guanethidine, Arg-Gly, L-arginine methyl ester, and L-argininamide, inhibited the transport of ranitidine, whereas other guanidine-containing compounds with an additional negative charge, e.g., L-arginine, did not. 2,4, 6-Triaminopyrimidine (TAP), an inhibitor of paracelluar cationic conductance, also inhibited the transport of both ranitidine and famotidine. On the basis of these results, it is proposed that the saturable transport of ranitidine and famotidine across Caco-2 cell monolayers appears to be via a facilitated diffusion process mediated by the paracellular anionic sites. This mechanism is consistent with the observation that ranitidine and famotidine caused a concentration-dependent increase in transepithelial electrical resistance (TEER) across Caco-2 cell monolayers, presumably by blocking the paracellular anionic sites and thus inhibiting the flux of cations (e.g., Na+).
Division of Drug Delivery and Disposition, School of Pharmacy, CB# 7360, Beard Hall, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599-7360, USA.
K
K
Lee
D R
DR
Thakker
D001692:Biological Transport; D018938:Caco-2 Cells; D017097:Electric Impedance; D015738:Famotidine / Q000493:pharmacokinetics* / Q000494:pharmacology; D019791:Guanidine / Q000494:pharmacology; D006635:Histamine H2 Antagonists / Q000493:pharmacokinetics*; D006801:Humans; D010042:Ouabain / Q000494:pharmacology; D011899:Ranitidine / Q000493:pharmacokinetics* / Q000494:pharmacology; D019810:Sodium Azide / Q000494:pharmacology
D006635:Histamine H2 Antagonists; D010042:Ouabain; D015738:Famotidine; D011899:Ranitidine; D019810:Sodium Azide; D019791:Guanidine